Analytical Data
-
Gene name
RRAGA
- Application
-
Alternative Names
Adenovirus E3 14.7KDA-interacting protein 1FIP-1
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7L523
-
Expression Region
1-247aa
-
Molecular Weight
56.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RRAGA (Ras-related GTPase A) is a member of the small GTPase family, playing a crucial role in the regulation of mTOR (mechanistic target of rapamycin) signaling, which is pivotal for cellular growth, metabolism, and proliferation. Dysregulation of the mTOR pathway is implicated in various diseases, including cancer and metabolic disorders. Recent studies have highlighted the importance of RRAGA in mediating amino acid signals to mTOR and facilitating its activation, thereby linking nutrient availability to cellular signaling pathways. The exploration of RRAGA as a potential therapeutic target has gained momentum, prompting the need for the production and characterization of recombinant RRAGA proteins. This enables researchers to investigate its structural properties, interaction with other cellular partners, and its role in modulating mTOR signaling under different physiological conditions. The development of recombinant RRAGA proteins has significant implications for understanding the molecular mechanisms governing cell growth and metabolism, with potential applications in the design of novel therapeutic strategies against mTOR-related diseases.
